DAX24.129 -0,1%Est505.883 -0,2%MSCI World4.343 -0,1%Top 10 Crypto9,8600 -1,2%Nas24.805 +1,5%Bitcoin66.384 -0,9%Euro1,1712 +0,3%Öl104,3 -1,6%Gold4.721 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SAP 716460 Rheinmetall 703000 Siemens Energy ENER6Y Infineon 623100 Intel 855681 NVIDIA 918422 Deutsche Telekom 555750 Lufthansa 823212 AMD (Advanced Micro Devices) 863186 Amazon 906866 Microsoft 870747 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Allianz 840400 TUI TUAG50
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen: Gute Laune bei Tech-Aktien -- DAX geht schwächer ins Wochenende -- SAP-Gewinn steigt stärker als erwartet -- Intel kehrt in die Gewinnzone zurück -- Tesla, Commerzbank, Newmont im Fokus
Top News
Analysten nehmen die Royal Gold-Aktie ins Visier: Wachstumsstory trifft auf attraktives Kurspotenzial Analysten nehmen die Royal Gold-Aktie ins Visier: Wachstumsstory trifft auf attraktives Kurspotenzial
Favoriten der Finanzprofis: Diese Aktien empfehlen Experten zu kaufen Favoriten der Finanzprofis: Diese Aktien empfehlen Experten zu kaufen
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Heron Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
0,8460 EUR +0,0065 EUR +0,77 %
STU
1,07 USD +0,07 USD +6,50 %
BTT
finanzen.net zero
Heron Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.164,68 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XB6K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4277461020

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHRTX

Heron Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
PR NewswireHeron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
PR NewswireHeron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
Wer­bungHeron Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireHeron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
PR NewswireHeron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025
PR NewswireHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
PR NewswireHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
PR NewswireHeron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer
PR NewswireHeron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025
PR NewswireHeron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
PR NewswireHeron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025
PR NewswireHeron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
PR NewswireHeron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
PR NewswireHeron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
PR NewswireHeron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
PR NewswireHeron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
PR NewswireHeron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PR NewswireHeron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
PR NewswireHeron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance
PR NewswireHeron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024
PR NewswireHeron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
PR NewswireHeron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
PR NewswireHeron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
PR NewswireHeron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
PR NewswireHeron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
PR NewswireHeron Therapeutics to Host Investor Day on May 15, 2024 in New York City
PR NewswireHeron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
PR NewswireHeron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
PR NewswireHeron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024
PR NewswireHeron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
PR NewswireHeron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain
PR NewswireHeron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
PR NewswireHeron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023
PR NewswireHeron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates
PR NewswireHeron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
PR NewswireHeron Therapeutics Announces Cost Reduction Plan and Restructuring
PR NewswireHeron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer
PR NewswireHeron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer
PR NewswireHeron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
PR NewswireHeron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

Heron Therapeutics News

Heron Therapeutics News: auf dieser Seite finden Sie alle Heron Therapeutics News und Nachrichten zur Heron Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Heron Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Heron Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.